Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Biotechnology (3)
- Colleges and universities (3)
- Pharmaceuticals (3)
- Research and development (3)
- Bayh-Dole Act (2)
-
- Biomedicine (2)
- Drug approvals (2)
- Drugs (2)
- Patentability (2)
- Scientific research (2)
- Commercial development (1)
- Competition (1)
- Corporations (1)
- DNA sequences (1)
- Drug Price Competition and Patent Term Restoration Act (1)
- Exclusivity (1)
- Federal Circuit (1)
- Federal agencies (1)
- Food and Drug Administration (1)
- Funding (1)
- Funding agencies (1)
- Genetics (1)
- Genome (1)
- Industries (1)
- Licensing (1)
- National Institutes of Health (1)
- Patent and Trademark Office (1)
- Patent applications (1)
- Patent infringement (1)
- Publication
Articles 1 - 4 of 4
Full-Text Articles in Food and Drug Law
Reaching Through The Genome, Rebecca S. Eisenberg
Reaching Through The Genome, Rebecca S. Eisenberg
Book Chapters
The past two decades have been a period of rapid evolution in the science of biotechnology and therefore in patent strategies, if not in patent law itself. Patent law takes a long time to catch up with science, and commentators take a long time to catch up with the law, but patent lawyers don’t have that luxury. They have to keep ahead of the game, figuring out claiming strategies that allow their clients to capture the value of future discoveries. I want to discuss some of these strategies today.
Bayh-Dole Reform And The Progress Of Biomedicine, Arti K. Rai, Rebecca S. Eisenberg
Bayh-Dole Reform And The Progress Of Biomedicine, Arti K. Rai, Rebecca S. Eisenberg
Articles
Advances in fundamental biomedical research play an important and growing role in the development of new therapeutic and diagnostic products. Although the development of pharmaceutical end products has long been a proprietary enterprise, biomedical research comes from a very different tradition of open science. Within this tradition, long-standing norms call for relatively unfettered access to fundamental knowledge developed by prior researchers. The tradition of open science has eroded considerably over the past quarter century as proprietary claims have reached farther upstream from end products to cover fundamental discoveries that provide the knowledge base for future product development.
Patents, Product Exclusivity, And Information Dissemination: How Law Directs Biopharmaceutical Research And Development, Rebecca S. Eisenberg
Patents, Product Exclusivity, And Information Dissemination: How Law Directs Biopharmaceutical Research And Development, Rebecca S. Eisenberg
Other Publications
It's a great honor for me to be invited to deliver the Levine Distinguished Lecture at Fordham, and a great opportunity to try out some new ideas before this audience. As some of you know, I've been studying the role of patents in biomedical research and product development ("R&D") for close to twenty years now, with a particular focus on how patents work in "upstream" research in universities and biotechnology companies that are working on research problems that arise prior to "downstream" product development. But, of course, the patent strategies of these institutions are designed around the profits that everyone …
Bayh-Dole Reform And The Progress Of Biomedicine, Arti K. Rai, Rebecca S. Eisenberg
Bayh-Dole Reform And The Progress Of Biomedicine, Arti K. Rai, Rebecca S. Eisenberg
Articles
Allowing universities to patent the results of government-sponsored research sometimes works against the public interest.